A CITF-supported study, published in preprint and not yet peer-reviewed, found that two doses of mRNA vaccine (Pfizer or Moderna) produce robust antibody responses three months post-vaccination in both children and adults. Additionally, hybrid immunity (immunity derived from the combination of SARS-CoV-2 infection and vaccination) conferred stronger immune responses in both age groups when compared to vaccination alone.